Sign up

Avoro Capital Advisors LLC

$11.1B assets · 26 holdings · Q2 2026 · Filed 14 AUG 2026

About Avoro Capital Advisors LLC’s 13F portfolio

Avoro Capital Advisors LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Avoro Capital Advisors LLC reported $11.1B across 26 US-listed positions (). Its largest position is UNITED THERAPEUTICS CORP (UTHR) at 14% of the reported book, and its ten biggest holdings make up 79% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$11.1B
Assets (13F)
#448
of 8,845 by size
26
Holdings
79%
Top-10 weight
14
Buys
10
Sells
Top holdings · Q2 2026
26 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: UTHR
UNITED THERAPEUTICS CORP
$559.10
−3.16%
14%
2.8M$1.5B
2
NASDAQ: ASND
ASCENDIS PHARMA
$255.96
−5.32%
12%
5.1M$1.4B
3
NASDAQ: KRYS
KRYSTAL BIOTECH INC
$315.82
+0.15%
9.6%
2.9M$1.1B
4
NASDAQ: MDGL
MADRIGAL PHARMACEUTICALS INC
$396.74
−0.34%
8.8%
1.8M$984.4M
5
NASDAQ: ARGX
ARGENX SE
$942.04
+0.08%
8.3%
1.0M$927.8M
6
NASDAQ: ARWR
ARROWHEAD PHARMACEUTICALS INC
$43.65
+1.25%
8.3%
11.4M$925.6M
7
NASDAQ: KYMR
KYMERA THERAPEUTICS INC
$119.39
−1.44%
7.7%
7.5M$857.1M
8
NASDAQ: RVMD
REVOLUTION MEDICINES INC
$159.43
−0.24%
3.9%
2.3M$430.2M
9
NASDAQ: CYTK
CYTOKINETICS INC
$51.46
+0.27%
3.8%
5.0M$425.9M
10
NASDAQ: CELC
CELCUITY INC
$56.31
+1.28%
3.2%
3.4M$355.7M
11
NASDAQ: GPCR
STRUCTURE THERAPEUTICS INC
$17.12
−1.38%
3.2%
6.6M$351.8M
12
NASDAQ: XENE
XENON PHARMACEUTICALS INC
$37.56
−0.50%
3.1%
5.8M$348.7M
13
NASDAQ: DFTX
DEFINIUM THERAPEUTICS INC
—
—
3.0%
7.2M$338.2M
14
NASDAQ: QURE
UNIQURE NV
$20.23
−0.34%
2.8%
6.7M$309.9M
15
NASDAQ: VERA
VERA THERAPEUTICS INC
$26.75
+4.57%
2.2%
5.7M$245.6M
16
NASDAQ: TSHA
TAYSHA GENE THERAPIES INC
$3.77
−5.51%
1.5%
23.9M$162.7M
17
NASDAQ: OCUL
OCULAR THERAPEUTIX INC
$5.86
−1.35%
1.1%
12.5M$123.1M
18
NASDAQ: DMRA
DAMORA THERAPEUTICS INC
—
—
0.9%
3.8M$98.4M
19
NASDAQ: COAG
HEMAB THERAPEUTICS HLDGS INC
—
—
0.6%
1.9M$70.7M
20
NASDAQ: GHRS
GH RESEARCH PLC
$18.56
+1.70%
0.4%
1.8M$48.4M
21
NASDAQ: VRDN
VIRIDIAN THERAPEUTICS INC
$31.44
+4.38%
0.4%
2.5M$45.9M
22
NASDAQ: SEPN
SEPTERNA INC
$39.20
−0.63%
0.4%
1.3M$44.8M
23
NASDAQ: AVTX
AVALO THERAPEUTICS
$6.75
+0.75%
0.4%
2.3M$43.1M
24
NASDAQ: SNSE
FAETH THERAPEUTICS INC
$25.96
−28.23%
0.3%
1.4M$36.1M
25
NASDAQ: WHWK
WHITEHAWK THERAPEUTICS INC
$3.12
−0.32%
0.1%
2.8M$13.1M

Showing 1–25 of 26 positions on this page reported in this 13F.

Sector allocation
  • Healthcare95%
Recent activity · vs 2026-03-31
Bought14
  • AddedUTHRUNITED THERAPEUTICS CORP+5.6%$1.5B
  • NewASNDASCENDIS PHARMA—$1.4B
  • AddedMDGLMADRIGAL PHARMACEUTICALS INC+0.8%$984.4M
  • AddedARWRARROWHEAD PHARMACEUTICALS INC+6.1%$925.6M
  • AddedCYTKCYTOKINETICS INC+50.0%$425.9M
  • AddedCELCCELCUITY INC+0.7%$355.7M
  • AddedDFTXDEFINIUM THERAPEUTICS INC+43.8%$338.2M
  • AddedQUREUNIQURE NV+12.9%$309.9M
  • AddedTSHATAYSHA GENE THERAPIES INC+10.1%$162.7M
  • AddedOCULOCULAR THERAPEUTIX INC+1.8%$123.1M
Sold10
  • ReducedRVMDREVOLUTION MEDICINES INC−2.0%$430.2M
  • ReducedVERAVERA THERAPEUTICS INC−2.8%$245.6M
  • ReducedLXEOLEXEO THERAPEUTICS INC−20.6%$6.9M
  • SoldASNDASCENDIS PHARMA−100%—
  • SoldMNKDMANNKIND CORP−100%—
  • SoldALKSALKERMES PLC−100%—
  • SoldSLNOSOLENO THERAPEUTICS INC−100%—
  • SoldTERNTERNS PHARMACEUTICALS INC−100%—
  • SoldCNTACENTESSA PHARMACEUTICALS PLC−100%—
  • SoldAPLSAPELLIS PHARMACEUTICALS INC−100%—
5%+ Beneficial Ownership Stakes · 1 activist (13D) · 9 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
SCTX
Scribe Therapeutics, Inc.
13D16.4%3.1MFiled 30 JUL 2026
2
CNTA
Centessa Pharmaceuticals plc
13G10.0% · 2 classes14.6MFiled 17 FEB 2026
3
—
Tourmaline Bio, Inc.
13G9.9%2.6MFiled 14 AUG 2025
4
ARWR
Arrowhead Pharmaceuticals, Inc.
13G9.6% · 2 classes13.8MFiled 14 AUG 2026
5
GPCR
Structure Therapeutics Inc.
13G9.4%16.2MFiled 14 NOV 2025
6
VERA
Vera Therapeutics, Inc.
13G8.9% · 2 classes5.6MFiled 14 FEB 2025
7
COAG
Hemab Therapeutics Holdings, Inc.
13G7.1%3.3MFiled 14 AUG 2026
8
DMRA
Damora Therapeutics, Inc.
13G6.3%3.8MFiled 15 MAY 2026
9
FTH
Faeth Therapeutics, Inc.
13G5.5%1.4MFiled 16 NOV 2026
10
DFTX
Definium Therapeutics, Inc.
13G5.1%5.0MFiled 17 FEB 2026

Showing all 10 disclosed stakes. 2 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading Avoro Capital Advisors LLC’s 13F portfolio

Avoro Capital Advisors LLC’s $11.1B 13F book is spread across 26 reported positions and is highly concentrated — its ten largest positions alone are 79% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are UTHR, ASND, KRYS, MDGL and ARGX, led by UNITED THERAPEUTICS CORP (UTHR) at 14% of the portfolio. The heaviest sector exposure is Healthcare (95%).

What Avoro Capital Advisors LLC changed last quarter

Between 2026-03-31 and Q2 2026, Avoro Capital Advisors LLC was a net buyer: it opened 3 new positions and added to 11 more, while trimming 3 and closing 7 outright. Against a 26-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was UNITED THERAPEUTICS CORP (UTHR), and its biggest reduction was REVOLUTION MEDICINES INC (RVMD).

What a 13F does and doesn’t reveal

A 13F captures only Avoro Capital Advisors LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Avoro Capital Advisors LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Avoro Capital Advisors LLC's profile on this page is built directly from those filings.

How current is the 13F data on Avoro Capital Advisors LLC's page?

It reflects Avoro Capital Advisors LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Avoro Capital Advisors LLC files its next quarterly report, this page refreshes automatically.

Can I see Avoro Capital Advisors LLC's complete list of holdings?

This page highlights Avoro Capital Advisors LLC's largest positions rather than all 26 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Avoro Capital Advisors LLC's filings.

Does a 13F show everything Avoro Capital Advisors LLC owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Avoro Capital Advisors LLC's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Avoro Capital Advisors LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.